Arbutus Biopharma Corporation · NASDAQ:ABUS
Arbutus Biopharma — Technical Presentation (March 2020)
10 slides from Arbutus Biopharma's technical presentation, Mar 26, 2020
Slide 1: AB-729-001 Preliminary Results
AB-729-001 Preliminary Results March 26, 2020 NASDAQ: ABUS www.arbutusbio.com
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward- looking information within the meaning of Canadian securities laws (collectively,
Slide 3: AB-729-001 Study Design
AB-729-001 Study Design PART 1: Single Ascending Dose PART 2: Single Doses PART 3: Multiple Doses In Healthy Subjects In Chronic Hepatitis B Subjects In Chronic Hepatitis B Subjects Cohort A: 180mg Dose 1 (60mg) Cohort E: 60mg HBV DNA - n=6; 4 active : 2 placebo n=6 HBV DNA - n=7 (≥ Day 15 Safety) (
Slide 4: Key Inclusion/Exclusion Criteria
AB-729-001 Key Inclusion/Exclusion Criteria 1. Documented chronic hepatitis B infection; confirmed HBeAg positive or negative 2. HBV-DNA at screening: a) For HBV-DNA negative subjects (on a NA for at least 6 months): HBV-DNA <LLOQ b) For HBV-DNA positive subjects: HBV-DNA ≥1,000 IU/mL 3. HBsAg ≥250
Slide 5: Subject Demographics
AB-729-001 Chronic Hepatitis B Subject Demographics Cohort A: 180mg (n=4) Cohort B: 60mg (n=6) Age (mean, range) 42.8 (35-53) 48.2 (33-56) Male Gender (n, percentage) 3 (75%) 3 (50%) Asian Race (n, percentage) 0 (0%) 3 (50%) Hepatitis B e-Antigen Negative (n, percentage) 3 (75%) 6 (100%) Baseline He
Slide 6: Healthy Volunteer Safety
AB-729-001: Healthy Volunteer Safety •No SAEs across all doses •15 AEs in total; 4 study drug-related AEs •Dose 1 (60 mg): • No clinically significant changes in vital signs, lab parameters or ECG abnormalities •Dose 2 (180 mg): • 1 Grade 1 drug-related AE (erythema at injection site) • 1 Lab abnorm
Slide 7: Subject Safety
AB-729-001: Chronic Hepatitis B Subject Safety •No SAEs across both doses. 12 AEs in total; 8 study drug-related AEs 180mg Cohort 60mg Cohort 6 related AEs in 3 subjects: 2 related AEs in 2 subjects: • 4 Grade 1 AEs – increased ALT and AST in 2 subjects • 2 Grade 1 AEs – injection site redness and i
Slide 8: Individual HBsAg Change From Baseline After a Single Dose of AB-729
Individual HBsAg Change From Baseline in Chronic Hepatitis B Subjects 29 Days After a Single Dose of AB-729 60 mg Cohort 180 mg Cohort Mean Day 29: -0.44 log10 IU/mL Mean Day 29: (n=3) -0.24 log10 IU/mL (n=6) Mean Day 29: Mean Day 29: -0.81 log10 IU/mL -0.51 log10 IU/mL (n=3) (n=4) -1.94 log10 IU/mL
Slide 9: Individual HBsAg Change After Single Dose of AB-729: Long Term Follow Up
Individual HBsAg Change From Baseline in Chronic Hepatitis B Subjects After a Single Dose of AB-729: Long Term Follow Up 180 mg HBsAg Nadir -1.94 log10 IU/mL -1.17 log IU/mL Mean Wk 12: 10 -0.73 log10 IU/mL -0.98 log10 IU/mL (n=4) -1.10 log10 IU/mL Mean Wk 12: •Reduction in HBsAg observed in two -0.
Slide 10: Q&A
“YArbutus BIOPHARMA Q&A
Arbutus Biopharma — Technical Presentation (March 2020) on 6ix